Study type

Study type

Non-interventional study

Scope of the study

Drug utilisation
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Retrospective database study
Study drug and medical condition

Name of medicine, other

Qvar

Anatomical Therapeutic Chemical (ATC) code

(R01AD08) fluticasone

Medical condition to be studied

Asthma
Population studied

Age groups

Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

18500
Study design details

Main study objective

The objective of this study is to investigate the real life effectiveness of ICS delivery of Fluticasone Propionate (FP) and Qvar® (beclomethasone dipropionate HFA) by pMDI with spacer compared to pMDI alone.

Outcomes

ATS exacerbations, Clinical exacerbationsRisk domain asthma controlOverall asthma controlTreatment successSABA useHospitalisationsAdherenceIncidence of oral thrush

Data analysis plan

Summary statistics will highlight differences in baseline variable distributions between treatment groups. These differences will be quantified using conditional logistic regression models. Treatment arms will be compared using t-test / Mann Whitney U-test (depending on distribution) for variables measured on the interval/ratio scale and using a chi square test for categorical variables.If the exploratory analysis shows significant differences between the cohorts prior to IPD, patients will be matched at IPD for key baseline characteristics, the matching criteria and matching ratio will be determined once the baseline data have been examined. Any residual differences between the treatment arms after matching that are considered to be potentially significant (p<0.10) and any variables predictive of the outcome will be adjusted for through further statistical modelling.